BACKGROUND: Human papillomavirus (HPV) infection has contributed to an increased incidence of squamous cell carcinoma of the head and neck (SCCHN). Fatigue is a major side effect of SCCHN and its treatment. However, to the authors' knowledge, the association between HPV and fatigue has not been examined to date, nor is it known whether HPV influences biological mechanisms of fatigue, including inflammation. METHODS: Patients with SCCHN who were without distant metastasis were assessed at baseline (pre-radiotherapy) and 1 month and 3 months postradiotherapy. Fatigue was measured using the Multidimensional Fatigue Inventory. Peripheral inflammation was assessed by plasma C-reactive protein (CRP), interleukin 1 receptor antagonist (IL-1ra), soluble tumor necrosis factor receptor 2 (sTNFR2), and IL-6. Mixed effect models were used to examine associations. RESULTS: A total of 94 patients who were newly diagnosed were enrolled; 53% had HPV-related tumors. Patients with HPV-unrelated tumors had higher fatigue and higher plasma CRP, sTNFR2, and IL-6 over time, especially at baseline and 3 months after intensity-modulated radiotherapy compared with those with HPV-related tumors (all P <.05). However, fatigue and plasma sTNFR2 increased more significantly from baseline to 1 month after radiotherapy in the HPV-related group compared with the HPV-unrelated group (both P <.01). Controlling for significant covariates, HPV status and inflammation were found to be independent predictors of fatigue over time. CONCLU-SIONS: HPV status is an important marker of vulnerability to the behavioral and immune consequences of SCCHN and its treatment, providing support for different symptom management strategies. Special emphasis should be placed on addressing marked persistent fatigue in patients with HPV-unrelated tumors, whereas attention should be paid to the large increases in fatigue during treatment among patients with HPV-related tumors. Cancer
INTRODUCTION
Head and neck cancer (HNC) is the sixth leading cancer by incidence worldwide 1 ; the estimate of new cases in the United States is approximately 61,760, 2 the majority of which are squamous cell carcinoma (SCC) cases. The incidence of SCC of the head and neck (SCCHN) has been consistently increasing in the United States, due mainly to the increased incidence of human papillomavirus (HPV) infection. 2 Patients with HPV-related SCCHN have better responses to treatment and better survival than patients with HPV-unrelated SCCHN. 3 However, to the best of our knowledge, studies to date have not explored the association between HPV status and cancer-related fatigue and whether HPV status plays a role in biological mechanisms related to fatigue, including inflammation. Fatigue is the most common side effect of cancer and its treatment. 4 Patients with SCCHN undergoing intensity-modulated radiotherapy (IMRT), a commonly used radiotherapy, experience even greater fatigue compared with patients treated with conventional radiotherapy. 5 Our previous studies on SCCHN have demonstrated that fatigue is consistently ranked among the top 3 severe side effects. 6, 7 Fatigue negatively affects patients' quality of life, functional status, 8 and adherence to medical treatment. 9 Pretreatment or posttreatment fatigue is prognostic of poor treatment response 10 and reduced survival for patients with cancer, including SCCHN. 11 However, the management of cancer-related fatigue remains challenging, and understanding the biological mechanisms of fatigue will help to reveal potential targets for intervention.
Inflammation has been proposed as one biological mechanism that contributes to cancer-related fatigue. 12 Our published findings have supported the positive association between inflammation and fatigue from before (pre) to 1 month after (post) treatment in patients with SCCHN. 7 Long-term follow-up with a larger sample size is necessary to verify and extend our understanding of this association. Moreover, to the best of our knowledge, the effect of HPV status on inflammation and fatigue has not been examined to date. Given recent published evidence of an association between HPV and improved quality of life, 13 we hypothesized that fatigue might differ as a function of HPV status, and that HPV may influence inflammatory profiles and their association with fatigue. Thus, the purpose of the current study was to assess the relationship between HPV status, inflammation, and fatigue in patients with SCCHN from pre-IMRT to 1 and 3 months post-IMRT.
MATERIALS AND METHODS

Participants and Procedures
The current study was a longitudinal, prospective study of patients with SCCHN receiving IMRT at radiation oncology clinics at Emory University between 2012 and 2015. Patients were studied before IMRT and at 1 and 3 months post-IMRT. All cancer treatments were completed upon completion of IMRT, and 1 month and 3 months post-IMRT are typical time points for clinical follow-up. The study was approved by the institutional review board of Emory University, and all subjects provided informed consent.
Inclusion criteria were histological proof of SCCHN, age 21 years, no evidence of uncontrolled major organ disease or immunologic conditions that might confound the relationship between fatigue and inflammation, and patients who were to receive IMRT with or without concurrent chemotherapy. Exclusion criteria included evidence of distant metastases, simultaneous primary tumors, pregnancy, and patients diagnosed with major psychiatric disorders or who could not understand English. Over-the-counter anti-inflammatory medications and antidepressants were allowed.
Patient eligibility was determined by reviewing the electronic medical record. After providing informed consent, eligible patients were enrolled before the initiation of IMRT. Demographic and clinical variables were collected at baseline and/or follow-up as appropriate. Behavioral measures were completed pre-IMRT, and then at 1 and 3 months post-IMRT. Blood samples for inflammatory markers were collected on the same day as the behavioral questionnaires were administered.
Measurements
Demographic and clinical variables were collected through patient-reported questionnaires or chart review. 6 Demographic variables included age, sex, race (white vs other), marital status (married vs other), tobacco use (current/history of vs not), and alcohol use (current/history of vs not). Clinical variables included HPV status (HPV related vs HPV unrelated), body mass index (BMI), antidepressant use (yes vs no), comorbidities (according to the Charlson Comorbidity Index), primary cancer site (oropharynx vs oral cavity vs larynx vs other), cancer stage (TNM stage I-III vs IV), radiotherapy dose, chemotherapy (yes vs no), chemotherapy regimen (cisplatin vs carboplatin/paclitaxel vs others) and surgery (yes vs no). p16 or HPV status was determined based on pathology reports of the tumor tissue before treatment and was obtained through chart review. According to current practice, p16-positive or HPV-positive status was counted as HPV related; otherwise it was considered to be HPV unrelated.
Fatigue, the primary outcome, was measured by the Multidimensional Fatigue Inventory (MFI). The MFI is a 20-item self-report instrument covering 5 dimensions of fatigue: 1) general fatigue; 2) physical fatigue; 3) mental fatigue; 4) reduced motivation; and 5) reduced activity.
14 Each dimension includes 4 items. The total score, ranging from 20 to 100 (with higher scores indicating more fatigue), is calculated as the sum of the 5 dimensions. The MFI has well-established validity and reliability (a 5 .84) in use with patients with cancer, 14 including SCCHN. 7 Other symptoms used as covariates included depressive symptoms, sleep problems, cognitive dysfunction, pain, dry mouth, difficulty swallowing, skin burn from radiation, mouth or throat sores, taste change, nausea, and vomiting. These were chosen based on literature reviews and our past studies. 6, 7, 12 All symptoms were measured by the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) initiated by the National Cancer Institute. 15 To reduce the number of variables in data analysis, 8 of the above-described symptoms were grouped into 2 symptom clusters as supported by our published studies. 6 These 2 symptom clusters were the HNC cluster (including pain, dry mouth, difficulty swallowing, skin burn from radiation, mouth or throat sores, and taste change) and the gastrointestinal (GI) cluster (including nausea and vomiting).
Whole blood was collected into chilled ethylenediaminetetraacetic acid (EDTA) tubes for plasma isolation. The time of collection was not standardized based on subject availability. Plasma was separated by centrifugation at 10003g for 10 minutes at 4 8C, and then aliquoted into siliconized polypropylene tubes and stored at -80 8C until batched assay. Plasma concentrations of interleukin 1
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Cancer receptor antagonist (IL-1ra), soluble tumor necrosis factor receptor 2 (sTNFR2), and IL-6 were determined in duplicate using Magnetic Luminex Screening Assay (R&D Systems, Minneapolis, Minnesota).
16,17 C-reactive protein (CRP) was measured using a standard turbidimetric assay. 7 Assay sensitivity was 39.01 pg/mL for IL-1ra, 5.72 pg/mL for sTNFR2, 0.17 pg/mL for IL-6, and 0.1 mg/ l for CRP. Mean intra-assay and interassay coefficients of variation were reliably <10%. All assay results were in the detectable range. These inflammatory markers were selected because of their association with cancer-related fatigue as noted in our previous studies of SCCHN and other cancers. 7 
Statistical Analysis
Descriptive statistics were performed for sample characteristics. Student t tests or chi-square tests were conducted to examine differences between HPV-related and HPVunrelated groups. Mixed effect models were used to examine whether HPV status was a predictor of inflammation or fatigue over time. Similar mixed effect models also were used to examine whether HPV and inflammation were predictors of fatigue. Covariates (demographic and clinical variables and other symptoms) with significant bivariate associations with inflammation or fatigue over time at P < .1 were adjusted for as fixed effects in the mixed effect models. Grand mean centering was used for inflammatory markers. A random subject intercept was included to account for correlations within subjects over time. Given the potential influence of diurnal patterns on inflammatory markers, 18 the blood collection time also was entered into the models. If a significant interaction effect with time was noticed for the covariates, their interaction effects were added into the models as well. A 2- 
RESULTS
A total of 94 patients were consented and enrolled; 35 of them were reported in our previous publication of pre-IMRT to 1 month post-IMRT. 7 Similarly, the sample was primarily white (88%), male (75%), and middle aged (aged 58 6 10 years). The majority of the participants had TNM stage III (31%) or IV (57%) disease, and 51% were diagnosed with oropharyngeal cancer. Approximately 77% received concurrent chemotherapy, among whom 65% received cisplatin. Patients with HPV-related tumors (53%) were significantly more likely to be male, have no history of tobacco use, have a higher BMI, be diagnosed with oropharyngeal cancer, receive concurrent chemoradiotherapy, and receive higher dose of radiotherapy (Table 1) .
Fatigue increased significantly from pre-IMRT to 1 month post-IMRT and remained increased at 3 months post-IMRT (45.44 6 15.68 vs 53.86 6 15.49 vs 51.80 6 17.84; P < .0001) for all patients. Patients with HPV-unrelated tumors experienced significantly higher levels of fatigue over the course of the study (P 5 .0097) ( Table 2 ), especially at pre-IMRT (P 5 .001) and 3 months post-IMRT (P 5 .002), compared with those with HPV-related tumors (Fig. 1A) . These findings were unchanged after controlling for significant covariates (Table 3) . It is interesting to note that treatment type, receipt of chemotherapy, or receipt of surgery were not found to be significant individual predictors of fatigue. Similar patterns were observed for inflammation as represented by plasma CRP, sTNFR2, and IL-6. Patients with HPV-unrelated tumors had significantly higher plasma levels of CRP (P < .0001), sTNFR2 (P 5 .0369), and IL-6 (P 5 .0064) over time (Table 2 ), especially at pre-IMRT (CRP: P < .0001; sTNFR2: P < .0001; and IL-6: P 5 .021) and 3 months post-IMRT (CRP: P 5 .005 and IL-6: P 5 .030) compared with those with HPV-related tumors (Fig. 1B) . Plasma CRP and sTNFR2 remained significantly associated with HPV over time after controlling for significant covariates of feeding tube and HNC cluster for CRP (P 5 .0003) and medical comorbidities, BMI, chemotherapy, and GI cluster for sTNFR2 (P 5 .0101).
It is interesting to note that compared with patients with HPV-unrelated tumors, patients with HPV-related tumors exhibited larger increases in fatigue and inflammation from pre-IMRT to 1 month post-IMRT, and larger Abbreviations: CRP, C-reactive protein; HPV, human papillomavirus; IMRT, intensity-modulated radiotherapy; IL-1ra, interleukin 1 receptor antagonist; IL-6, interleukin 6; SCCHN, squamous cell carcinoma of the head and neck; SD, standard deviation; sTNFR2, soluble tumor necrosis factor receptor 2. The mean and SD are raw scores. Mixed effect modeling was used to assess the effects of time and HPV status on fatigue and the inflammatory markers.
a Had missing data: HPV-related: 1 month after IMRT: fatigue (1); 3 months after IMRT: fatigue (1) and sTNFR2 (1). HPV-unrelated: before IMRT: IL-1ra (1), sTNFR2 (1), and IL-6 (1); 1 month after IMRT: IL-1ra (1) and IL-6 (1); 3 months after IMRT: fatigue (1), IL-1ra (1), and IL-6 (1).
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Cancer decreases in fatigue and inflammation from 1 month to 3 months post-IMRT (Fig. 1) . Thus, we conducted post Mixed effects modeling was used to examine the impact of inflammation (considering each inflammatory marker independently), HPV status, time, and their interaction (HPV status 3 time) on fatigue. The results indicated that inflammatory markers and HPV status 3 time were independent predictors of fatigue over time after adjusting for significant and relevant covariates including chemotherapy (Table 3) . Patients with higher levels of Abbreviations: CRP, C-reactive protein; GI, gastrointestinal; HNC, head and neck cancer; HPV, human papillomavirus; IL-1ra, interleukin 1 receptor antagonist; IL-6, interleukin 6; sTNFR2, soluble tumor necrosis factor receptor 2. Note. Multivariate mixed effect modeling was used to assess the effect of time, HPV status, and their interaction on fatigue as a function of each inflammatory marker individually. a Data were log10 transformed and centered by the grand mean. b The reference group was 3 months. c The reference group was the HPV-related group. d Fatigue was found to be significantly higher in the HPV-unrelated group at baseline and at 3 months after intensity-modulated radiotherapy but not at 1 month after intensity-modulated radiotherapy for all models including different inflammatory markers. e The reference group was chemotherapy group. HPV, Fatigue, and Inflammation/Xiao et al Cancer inflammation as represented by plasma CRP (estimate, 3.2670; P 5 .0103), IL-1ra (estimate, 5.8329; P 5 .0123), and sTNFR2 (estimate, 12.0137; P 5 .0063) were more likely to have higher fatigue during the course of the study. In addition, there were significant interaction effects between HPV and time on fatigue (Table 3) . Patients with HPV-unrelated tumors were more likely to experience higher fatigue at pre-IMRT and 3 months post-IMRT compared with those with HPV-related tumors, whereas fatigue was similar between the 2 groups at 1 month post-IMRT.
DISCUSSION
The findings of the current study indicate that HPV status is associated with levels of fatigue and inflammation before and after IMRT. Fatigue in patients with HPV-unrelated tumors was persistently high both pre-IMRT and post-IMRT, whereas patients with HPV-related tumors experienced lower levels of fatigue pre-IMRT and 3 months post-IMRT, but experienced a larger increase in fatigue from pre-IMRT to 1 month post-IMRT. These data support the idea that HPV status may play an important role in patient vulnerability to the effects of SCCHN and its treatment with regard to both fatigue and inflammation. The current study findings of higher levels of fatigue and inflammation in patients with HPV-unrelated tumors are consistent with our previously published studies regarding quality of life, in which patients with HPVunrelated SCCHN experienced worse quality of life before and after radiotherapy when compared with patients with HPV-related SCCHN. 13, 19, 20 It is interesting to note that the higher levels of fatigue and inflammation noted in patients with HPV-unrelated SCCHN at baseline and at 3 months post-IMRT in the current study were apparent even after considering surgery (typically 1 month before IMRT) and other clinical variables that differed between groups, including tumor site and stage of disease as well as treatment regimen in the analyses. Indeed, patients with HPV-related tumors were more likely to receive concurrent chemotherapy and radiotherapy, both of which have been associated with more fatigue and potentially more inflammation in previous studies. 21 It is unclear why fatigue and inflammation were high at baseline and remained high 3 months post-IMRT in the HPV-unrelated group; however, this finding suggests that patients in the HPV-unrelated group need continuous support for their symptom burden.
Another important observation was that patients with HPV-related tumors experienced a larger increase in fatigue 1 month post-IMRT compared with those without HPV. Inflammatory markers demonstrated a similar pattern. This change in fatigue over time also echoes our published study concerning quality of life, in which patients with HPV-related tumors experienced a larger decrease in quality of life at the end of radiotherapy than patients without HPV. 13 To the best of our knowledge, the reason behind this is unclear; however, it might be related to the lower baseline levels of fatigue and inflammation in these individuals. Given the similar intensive treatment regimens received by both groups at the time of the current study, this larger increase in fatigue and inflammation indicates that patients with HPVrelated disease are more likely to be affected by treatment intensity, further supporting the rationale for current dose reduction trials in patients with HPV-related SCCHN. 22 Given the significant association between HPV and oropharyngeal cancer, we also examined whether oropharyngeal cancer might be the major driver of the different fatigue and inflammation profiles observed as a function of HPV. Mixed effect models demonstrated that cancer site (oropharyngeal vs nonoropharyngeal) explained significant differences in plasma CRP levels, but not in fatigue and IL1-ra, sTNFR2, and IL-6 levels. Thus, the data from the current study suggested that HPV status, not the cancer site, plays a major role in the differences in fatigue and inflammation observed in these patients.
Fatigue in general was found to be significantly associated with inflammation in the patients in the current study. This positive association is consistent with previous evidence, 12, 23 and extends our published finding of positive associations between inflammation and fatigue to 3 months post-IMRT in patients with SCCHN. 7 Longer follow-up studies are warranted to explore whether this association persists long after the completion of cancer treatment and whether HPV plays a role in the long-term association. In addition, treatment type was not found to be significantly associated with fatigue, although treatment-associated side effects, such as HNC and GI clusters, were significant. HNC and GI clusters were found to be significantly higher in patients receiving carboplatin/paclitaxel compared with those receiving cisplatin. These data suggest that treatment types can play a role in some side effects, but not necessarily in fatigue, at least in the current study. More data are needed to further evaluate these associations.
The major strengths of the current study include a relatively large sample size and data collected prospectively and longitudinally. Nevertheless, with the longitudinal design, we had some missing data at 3 months post-IMRT, which might have biased the results. However, we performed sensitivity analyses, and with the exception of race and sex, there were no significant differences noted with regard to baseline measures, including fatigue and inflammatory markers, between subjects having missing data at 3 months and those without missing data at that time point. In addition, different fatigue and inflammation profiles in the HPV-related and HPV-unrelated groups should be interpreted with caution because other confounders might explain the differences, even though they were not significant in this study. Although the timing of blood collection and administration of behavioral surveys was included in the data analyses as a control variable (and was not found to be statistically significant), circadian variations in inflammatory markers (and potentially behavioral responses) also may have influenced the relationship among inflammation, fatigue, and HPV status. In addition, the heterogeneous nature of HNC sites, as noted in other published studies, represents a limitation. 24 However, cancer site did not significantly predict the relationship between inflammation and fatigue in the current study.
Conclusions
To the best of our knowledge, the current study is the first to date to report an association between HPV and behavioral and inflammatory responses to cancer and its treatment. Patients with HPV-unrelated tumors experienced persistently high levels of fatigue, even at 3 months post-IMRT, whereas patients with HPV-related tumors exhibited lower fatigue and inflammation at baseline and at 3 months posttreatment. However, patients with HPVrelated tumors experienced a larger increase in fatigue and inflammation from baseline to 1 month post-IMRT. These different symptom profiles suggest that clinicians may want to use different symptom management strategies for patients with or without HPV-related tumors. More specifically, patients with HPV-unrelated disease need constant support before and after treatment, whereas the 1-month post-IMRT time point is when patients with HPV-related tumors need the most attention. Studies with longer follow-up and larger sample sizes are needed to verify the current study findings, especially among patients with oropharyngeal cancer only. It also would be interesting to explore why patients with HPV-unrelated SCCHN have higher fatigue and inflammation than those with HPV-related SCCHN. 
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